Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter ...

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

Hungary was originally set to receive €21.7 billion from the EU for the 2021-2027 period, based on decisions made in December ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul ...

Tempus AI is trading at a forward 12-month price-to-sales (P/S) ratio of 7.90, below its median of 8.14 over the last year. Butterfly Network’s forward sales multiple sits at 5.00, below its ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Tempus' adjusted earnings before interest, taxes, depreciation and amortization of -$16.2 million in the first quarter was less than the $43.9 million adjusted EBITDA in the first quarter of 2024.

Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Joel South Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past ...